3ZO Stock Overview
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Acurx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$4.28 |
| 52 Week Low | US$0.67 |
| Beta | -1.71 |
| 1 Month Change | 6.74% |
| 3 Month Change | -58.75% |
| 1 Year Change | -77.37% |
| 3 Year Change | -79.59% |
| 5 Year Change | n/a |
| Change since IPO | -83.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3ZO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.0% | 2.5% | -0.4% |
| 1Y | -77.4% | -10.2% | 7.9% |
Return vs Industry: 3ZO underperformed the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: 3ZO underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 3ZO volatility | |
|---|---|
| 3ZO Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3ZO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3ZO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Dave Luci | www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. Fundamentals Summary
| 3ZO fundamental statistics | |
|---|---|
| Market cap | €14.59m |
| Earnings (TTM) | -€15.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 3ZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3ZO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.44m |
| Earnings | -US$16.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3ZO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 03:36 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acurx Pharmaceuticals, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Arce | H.C. Wainwright & Co. |
| null null | Independent Investment Research (Aust.) Pty Ltd |
| Jason McCarthy | Maxim Group |